TNON insider grant: Richard Ginn receives 253,153 RSUs

Rhea-AI Filing Summary

Tenon Medical (TNON) reported an insider equity grant. Director and Chief Technology Officer Richard Ginn received 253,153 restricted stock units (RSUs) on 10/13/2025. Each RSU represents the right to receive one share of common stock.

The RSUs vest in two equal tranches: 50% on January 1, 2026 and 50% on July 31, 2026. The filing lists the derivative security price as $0 and indicates direct ownership following the transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider GINN RICHARD

Role Chief Technology Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	253,153	$0.00	--

Holdings After Transaction: Restricted Stock Units — 253,153 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Fifty percent (50%) of the total number of restricted stock units shall vest and automatically convert into shares of common stock of the Issuer (on one-for-one basis) on January 1, 2026 and the remaining fifty percent (50%) shall vest and automatically convert into the shares of common stock of the Issuer (on one-for-one basis) on July 31, 2026.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

GINN RICHARD

(Last) (First) (Middle)

104 COOPER COURT

(Street)

LOS GATOS CA 95032

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tenon Medical, Inc. [ TNON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	10/13/2025		A		253,153		(2)	(2)	Common Stock	253,153	$0	253,153	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.

2. Fifty percent (50%) of the total number of restricted stock units shall vest and automatically convert into shares of common stock of the Issuer (on one-for-one basis) on January 1, 2026 and the remaining fifty percent (50%) shall vest and automatically convert into the shares of common stock of the Issuer (on one-for-one basis) on July 31, 2026.

	/s/ Richard Ginn	10/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Tenon Medical (TNON) disclose in this Form 4?

An equity grant to Director and CTO Richard Ginn of 253,153 RSUs on 10/13/2025.

How many RSUs were granted to Richard Ginn at TNON?

He received 253,153 restricted stock units.

What is the vesting schedule for the TNON RSUs?

The RSUs vest 50% on January 1, 2026 and 50% on July 31, 2026.

What does each TNON RSU represent?

Each RSU represents a contingent right to receive one share of common stock.

What ownership form is shown after the transaction?

The filing indicates direct (D) ownership.

What price is listed for the derivative security in the filing?

The derivative security price is listed as $0.

What roles does the reporting person hold at Tenon Medical (TNON)?

Richard Ginn is a Director and the Chief Technology Officer.